Checkpoint Inhibitors Global Market Report 2024

The checkpoint inhibitors market size has grown rapidly in recent years. It will grow from $32.41 billion in 2023 to $37.88 billion in 2024 at a compound annual growth rate (CAGR) of 16.9%. The growth observed in the historical period can be attributed to several factors, including the escalating incidence of cancer cases, heightened awareness surrounding checkpoint inhibitors, the broadening spectrum of approved checkpoint inhibitors, active research and development endeavors focused on novel checkpoint inhibitors, and the proliferation of clinical trials and extensive research in this field.

The checkpoint inhibitors market size is expected to see rapidly grown in the next few years. It will grow to $55.64 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%. Anticipated growth in the forecast period is expected to stem from several factors, notably the expansion of indications for checkpoint inhibitors, ongoing discoveries in biomarkers, the evolution of combination therapies, the increasing focus on personalized medicine, and the continued broadening of indications.

The surge in global cancer cases is poised to drive the checkpoint inhibitors market, buoyed by a projected increase in new diagnoses and cancer-related deaths, as highlighted by the American Cancer Society in January 2022. With prevalent cancers like lung, prostate, bowel, and female breast cancer constituting a significant percentage of new cases, the efficacy of checkpoint inhibitors targeting these checkpoints stands pivotal in cancer therapy. The market for these inhibitors is expected to surge in response to the escalating rates of cancer incidence worldwide.

The checkpoint inhibitors market is set to expand further, propelled by a concurrent rise in healthcare expenditure. This expenditure encompasses a spectrum of activities, from drug development to patient access and support. Notably, the Office for National Statistics reported a substantial increase in healthcare spending in the UK between 2020 and 2021, reflecting a heightened investment in pharmaceuticals and preventive care. Such augmented healthcare expenditure is a key driver behind the growth of the checkpoint inhibitors market. Major players in the checkpoint inhibitor realm are forging strategic partnerships to advance technologies like bifunctional fusion proteins or Y-trap, aiming to enhance the efficacy of immunotherapies. In June 2021, Merck and GSK's global strategic partnership to develop and market M7824 (bintrafusp alfa), an investigational bi-functional fusion protein immunotherapy, exemplifies this trend. Similarly, collaborations like GSK's alliance with ITeos Therapeutics seek to leverage expertise in immuno-oncology to expedite the development and commercialization of innovative therapies such as EOS-448.

Keytruda (pembrolizumab), an immunotherapy drug categorized as a checkpoint inhibitor, exemplifies the innovation in the checkpoint inhibitors market. Merck & Co., Inc. Obtained FDA approval in March 2022 for Keytruda to treat patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) advanced endometrial carcinoma. Keytruda's mechanism involves enabling the immune system to identify and combat cancer cells by blocking checkpoint proteins, offering an effective treatment avenue either individually or in combination with other cancer therapies.

In November 2021, Pfizer Inc., a US-based pharmaceutical industry company, acquired Trillium Therapeutics Inc. For $2.22 billion. Through this acquisition, Pfizer aims to strengthen its oncology portfolio with the addition of next-generation investigational immunotherapeutics for hematological malignancies and gain access to Trillium's two lead molecules. Trillium Therapeutics Inc. Is a US-based biotech company developing innovative checkpoint inhibitors for the treatment of cancer.

Major companies operating in the checkpoint inhibitors market include AstraZeneca PLC, Bristol-Myers Squibb Company, Merck & Co. Inc., Roche Holding AG, Pfizer Inc., Incyte Corporation, Novartis AG, NewLink Genetics Corporation, Seattle Genetics Inc., Celldex Therapeutics, GlaxoSmithKline PLC, Innate Pharma S.A., Ono Pharmaceutical Co. Ltd., Juno Therapeutics, Kite Pharma, Eli Lilly and Company (ARMO Biosciences.), Fortress Biotech, Argenx SE, MacroGenics, CureTech, Sorrento Therapeutics, Sanofi S.A, F. Hoffmann-La Roche Ltd., AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Kyowa Kirin Co. Ltd., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Y-mAbs Therapeutics Inc., Zai Lab Limited.

North America was the largest region in the checkpoint inhibitors market in 2023. The Middle East is expected to be the fastest growing region in the global checkpoint inhibitors market share during the forecast period. The regions covered in the checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the checkpoint inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

Within the realm of checkpoint inhibitors, the primary drug categories include PD-1 inhibitors, PD-L1 inhibitors, CTLA-4 inhibitors, chimeric antigen receptor T-cells (CAR-T), and other variants. PD-1 and PD-L1 inhibitors specifically hinder the function of immune checkpoint proteins present on cell surfaces, aiding in the treatment of conditions like lung cancer, renal cancer, blood cancer, bladder cancer, melanoma, and more. These therapies find application across diverse sectors encompassing hospital pharmacies, retail pharmacies, and online pharmacy services.

The checkpoint inhibitors market research report is one of a series of new reports provides checkpoint inhibitors market statistics, including checkpoint inhibitors industry global market size, regional shares, competitors with a checkpoint inhibitors market share, detailed checkpoint inhibitors market segments, market trends and opportunities, and any further data you may need to thrive in the checkpoint inhibitors industry. This checkpoint inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The checkpoint inhibitors market consists of sales of atezolizumab, avelumab, and durvalumab. Values in this market are 'factory gate values,' that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.